Legato Capital Management’s AtriCure ATRC Stock Holding History

Legato Capital Management’s Portfolio ATRC Stock Details ATRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-24,535	Closed	-$1.07M	–	572
2023 Q3	$1.07M	Sell	24,535 -640	-3%	-$31.2K	0.16%	220
2023 Q2	$1.24M	Buy	25,175 +7,144	+40%	+$329K	0.17%	200
2023 Q1	$747K	Buy	+18,031	New	+$748K	0.14%	256

Other funds holding ATRC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Legato Capital Management's ATRC Position: Q4 2023 in Review

Legato Capital Management sold out of AtriCure (ATRC) in Q4 2023, closing a stake of 24,535 shares — an estimated $1.07M sold.

Legato Capital Management first reported a position in ATRC in Q1 2023 and held it in 3 quarters. The position peaked at $1.24M in Q2 2023. 233 funds tracked by Wall St. Rank hold ATRC as of Q4 2023.

Legato Capital Management reported no remaining AtriCure position as of Q4 2023 after selling out during the quarter.
Legato Capital Management sold 24,535 AtriCure shares in Q4 2023, an estimated $1.07M.
Legato Capital Management first reported a position in AtriCure in Q1 2023 and held it in 3 quarters.
Legato Capital Management's AtriCure position peaked at $1.24M in Q2 2023.
233 funds tracked by Wall St. Rank held AtriCure as of Q4 2023.

Based on Legato Capital Management's 13F filing for Q4 2023, filed 16 Jan 2024.